Pol F Boudes
CIK 1454771 · View on SEC EDGAR ↗
First SEC filing: March 29, 2021 · Latest: March 29, 2021
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Jan. 24, 2024 | GALT | A | 40,000 | — | — | 40,000 Direct | — | Acquired | (price as of 2026-08-21) |
| Jan. 24, 2024 | GALT | A | 65,000 | — | — | 65,000 Direct | — | Acquired | (price as of 2026-08-21) |
| Jan. 26, 2023 | GALT | A | 50,000 | — | — | 50,000 Direct | — | Acquired | (price as of 2026-08-21) |
| Jan. 24, 2022 | GALT | A | 50,000 | — | — | 50,000 Direct | — | Acquired | (price as of 2026-08-21) |
| March 25, 2021 | GALT | A | 100,000 | — | — | 100,000 Direct | — | Acquired | (price as of 2026-08-21) |
| March 25, 2021 | GALT | A | 50,000 | — | — | 50,000 Direct | — | Acquired | (price as of 2026-08-21) |
| March 12, 2020 | GALT | A | 300,000 | — | — | 300,000 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 24, 2024 | GALT | Restricted Stock Unit | Common Stock (40,000) | — | — | 40,000 | Acquired |
| Jan. 24, 2024 | GALT | Stock Option (right to buy) [F1] | Common Stock (65,000) | $1.11 | Jan. 24, 2034 | 65,000 | Acquired |
| Jan. 26, 2023 | GALT | Stock Option (right to buy) [F1] | Common Stock (50,000) | $1.11 | Jan. 26, 2033 | 50,000 | Acquired |
| Jan. 24, 2022 | GALT | Stock Option (right to buy) [F1] | Common Stock (50,000) | $1.98 | Jan. 24, 2032 | 50,000 | Acquired |
| March 25, 2021 | GALT | Stock option (right to buy) [F1] | Common Stock (100,000) | $2.11 | March 25, 2031 | 100,000 | Acquired |
| March 25, 2021 | GALT | Stock option (right to buy) [F1] | Common Stock (50,000) | $2.11 | March 25, 2031 | 50,000 | Acquired |
| March 12, 2020 | GALT | Stock option (right to buy) [F1] | Common Stock (300,000) | $1.75 | March 12, 2030 | 300,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
GALT
M.D., Former Chief Medical Officer(11)| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $530,000 | $160,500 | — | $39,946 | — | — | $39,834 | $770,280 |
| 2022 | $473,333 | $142,500 | — | $73,940 | — | — | $104,804 | $794,577 |
| 2021 | $452,583 | $136,500 | — | $235,126 | — | — | $99,474 | $923,683 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.